Introduction
============

A number of biochemical, physiological and behavioral processes have demonstrated that an internal time-keeping mechanism, referred to as the biological clock, regulates circadian rhythms. The master circadian clock coordinates peripheral clocks elsewhere in the body and is located in the suprachiasmatic nuclei (SCN) within the anterior hypothalamus ([@b1-ol-0-0-6876]). The core oscillator driving this clock is intergrated by an auto-regulatory transcription-(post) translation-based feedback loop, which is comprised of genes related to the circadian rhythm ([@b1-ol-0-0-6876],[@b2-ol-0-0-6876]).

Epidemiological studies have suggested that disruption of the circadian clock may increase cancer risk in humans ([@b3-ol-0-0-6876]--[@b5-ol-0-0-6876]). In particular, it has been observed that shift workers have an increased risk of developing malignancies, including breast, endometrial, prostate and colorectal cancer, due to their disrupted circadian cycles ([@b5-ol-0-0-6876]--[@b9-ol-0-0-6876]). Fu *et al* ([@b10-ol-0-0-6876]) previously demonstrated that a period circadian protein homolog 2 (*Per2*) mutation induced upregulation of c-Myc and downregulation of p53 transcription in mice; furthermore, the incidence of spontaneous and radiation-induced lymphoma increased, as did lymphoma-associated mortality. Other *in vivo* studies have identified an association between alterations of the circadian rhythm and tumorigenesis ([@b2-ol-0-0-6876],[@b9-ol-0-0-6876],[@b11-ol-0-0-6876]). In a number of types of human solid cancer, including breast, endometrial and colorectal cancer, the dysregulated expression of circadian genes has been investigated by immunohistochemistry and/or reverse transcription quantitative polymerase chain reaction (RT-qPCR) ([@b9-ol-0-0-6876],[@b12-ol-0-0-6876]--[@b14-ol-0-0-6876]).

The aim of the present study was to investigate the clinical significance of the mRNA expression of clock genes in human colorectal carcinoma and adenoma tissues, using *in situ* hybridization.

Patients and methods
====================

### Patients and tumor samples

A total of 51 patients (32 males and 19 females) with colorectal carcinoma, and 10 patients with colorectal adenoma were examined. All patients underwent endoscopic or surgical resection to completely remove tumors in the Department of Organ Regulatory Surgery, Fukushima Medical University Hospital (Fukushima, Japan) between April 1999 and July 2005. In several tissue specimens, the surrounding normal mucosa was also examined. None of the patients had received prior chemotherapy or irradiation or had experienced any other form of cancer. The clinicopathological characteristics of the 51 patients with colorectal cancer investigated in this study are summarized in [Table I](#tI-ol-0-0-6876){ref-type="table"}.

All tissue samples were embedded in optimal cutting temperature (OCT) compound (Sakura Finetek USA, Inc., Torrance, CA, USA) and immediately stored at −8°C. Tumors were histopathologically classified as well-differentiated, moderately differentiated, poorly differentiated or mucinous adenocarcinomas ([@b15-ol-0-0-6876]), and tumor size was defined as the largest diameter of the tumor. Histopathological diagnoses were performed at the Department of Pathology, Fukushima Medical University Hospital following standard procedures. Informed consent was obtained from each patient and the Fukushima Medical University Committee approved the protocol of the present study.

### In situ hybridization

Digoxigenin (DIG)-UTP labeled cRNA probes were used to evaluate the mRNA expression of clock genes. The DIG-labeled cRNA probes were synthesized using a DIG RNA Labeling kit (Roche Diagnostics, Basel, Switzerland), and were labeled with SP6 or T7 RNA polymerase in the presence of DIG-UTP. Sections 5-µm thick were formed from the embedded tissue specimens, sufficiently dried with cold air and fixed in 4% paraformaldehyde diluted with phosphate-buffered saline for 30 min. Sections were hybridized overnight at 42°C in hybridization buffer containing 1 µg/ml of DIG-labeled probe. The DIG-labeled probes were diluted to 1 µg/ml with hybridization buffer (Nippon Gene Co., Ltd., Tokyo, Japan) and dropped to the sections, which were incubated at 42°C for 16--20 h to hybridize with each probe. Following hybridization, the sections were washed in 2 × standard citrate buffered saline and 0.2 × saline sodium citrate buffer at 5°C for 20 min and treated with 1% blocking solution at room temperature for 30 min, using the DIG Nucleic Acid Detection Kit (Roche Diagnostics). The sections were subsequently incubated at room temperature for 30 min with alkaline phosphatase labeled anti-digoxigenin antibody (Roche) diluted with a blocking solution (1:5,000). Color reaction was conducted using NTB/BCIP at 4°C for 12 h. As a negative control, the serial section was hybridized with a sense probe. Sections were simultaneously evaluated by two investigators. The tumor cells were classified into 4 groups based on intensity of staining (none, weak, moderate or strong) indicating levels of gene expression within the cells.

### Statistical analysis

Differences between groups were evaluated by the χ^2^ test, Fisher\'s exact test, Student\'s *t* test or the Mann-Whitney U test. Cumulative survival was estimated by the Kaplan-Meier method and differences were analyzed by the log-rank test. All statistical analyses were two-sided and P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Potential involvement of clock genes in colorectal tumor progression

mRNA expression of the clock genes, including *Per1* and *2*, cryptochrome 1 (*Cry1*), circadian locomoter output cycles protein kaput (*Clock*), brain and muscle ARNT-like protein 1 (*Bmal1*) and casein kinase 1ε (*CK1*ε), was examined in colorectal cancer tissues by *in situ* hybridization. As presented in [Fig. 1](#f1-ol-0-0-6876){ref-type="fig"}, sense probes as negative controls exhibited no staining ([Fig. 1](#f1-ol-0-0-6876){ref-type="fig"} panels 3--4), whereas various levels of staining were observed in tumor cells detected by anti-sense probes ([Fig. 1](#f1-ol-0-0-6876){ref-type="fig"}, panels 1--2). Normal epithelial areas were evaluated in a number of specimens where the surrounding normal mucosa was available, however, no clear staining was detected by any of the probes ([Fig. 1](#f1-ol-0-0-6876){ref-type="fig"}. panels 5--6). The levels of expression of clock genes in tumor cells were classified into four groups (none, weak, moderate or strong), based on the intensity of staining ([Fig. 2](#f2-ol-0-0-6876){ref-type="fig"}). Tumors with no or weak staining were further defined as a negative group, while tumors with moderate and strong staining were a positive group. Of the 51 colorectal carcinomas evaluated, positive staining for *Per1*, *Per2*, *Cry1*, *Clock*, *Bmal1* and *CK1*ε was observed in 24 (47%), 26 (51%), 24 (47%), 21 (41%), 20 (39%) and 14 (27%) tumors, respectively ([Table I](#tI-ol-0-0-6876){ref-type="table"} and [Fig. 3](#f3-ol-0-0-6876){ref-type="fig"}). However, no significant associations were observed between levels of clock gene expression and histopathological type, depth of invasion, lymph node metastasis or disease stage ([Table I](#tI-ol-0-0-6876){ref-type="table"}). Although positive *Per2* and positive *Clock* groups tended to be associated with a deeper depth of invasion and advanced stage, respectively, these associations were not significance (P=0.052 and P=0.064, respectively). By contrast, positive-*Per1*, *Per2* and *Clock* groups were each associated with larger tumor size (\>50 mm; P=0.012, P=0.011 and P=0.009, respectively; [Table I](#tI-ol-0-0-6876){ref-type="table"}). Similar results were obtained when tumor size was treated as a continuous variable ([Fig. 4](#f4-ol-0-0-6876){ref-type="fig"}), therefore, the potential prognostic significance of *Per1*, *Per2* and *Clock* was investigated. No association was observed between *Per1* or *Clock* positive expression and overall survival rates (P=0.0599 and P=0.994, respectively; [Fig. 5A and B](#f5-ol-0-0-6876){ref-type="fig"}). On the other hand, patients with carcinomas exhibiting positive-*Per2* expression tended to have lower rates of survival than patients with negative-*Per2* carcinomas, although this association was not significant (P=0.060; [Fig. 5C](#f5-ol-0-0-6876){ref-type="fig"}).

### The expression of clock genes in colorectal adenoma

To investigate the expression of clock genes in precancerous lesions compared with cancer tissues, 10 colorectal adenomas were examined by *in situ* hybridization. In contrast to cancer tissues, the expression of each clock gene was undetectable in the majority of adenoma tissue ([Fig. 3](#f3-ol-0-0-6876){ref-type="fig"}). No adenomas (0%) exhibited positive staining for *Per1*, *Per2*, *Cry1*, *Bmal1* or *CK1*ε and only 10% of adenomas exhibited positive expression of *Clock*. Hence, the proportion of tissues indicating positive *Per1*, *Per2*, *Cry1* and *Cry2* expression in colorectal carcinoma was significantly higher than in colorectal adenoma (P=0.046, P=0.004, P=0.004 and P=0.015, respectively; [Fig. 3](#f3-ol-0-0-6876){ref-type="fig"}).

Discussion
==========

Epidemiological studies have suggested that disruption of the circadian rhythm is associated with increased cancer incidence and poorer disease outcome ([@b3-ol-0-0-6876]--[@b5-ol-0-0-6876],[@b8-ol-0-0-6876]). Previous studies have indicated that in Per2 mutant mice, *Bmal1* expression decreased causing an increase in c-Myc transcription, thus disrupting the circadian rhythm and increasing cancer risk ([@b10-ol-0-0-6876]). In colorectal cancer, animal studies using chemically induced models as well as APC^Min^/^+^ mice, have suggested a link between alterations of circadian genes and colorectal tumor development and progression ([@b16-ol-0-0-6876]--[@b18-ol-0-0-6876]). Other studies have used RT-qPCR to demonstrate that clock gene expression is dysregulated in human colorectal cancer ([@b9-ol-0-0-6876],[@b19-ol-0-0-6876],[@b20-ol-0-0-6876]).

In the present study, unlike previous studies, the *in situ* hybridization technique was utilized to detect clock gene mRNA expression in colorectal tumor tissues, including precancerous and cancerous lesions. The proportion of colorectal carcinomas with positive *Per1*, *Per2*, *Cry1* and *Cry2* expression was observed to be significantly higher than the proportion of adenomas, suggesting that dysregulated clock gene expression may be involved in colorectal tumorigenesis. Colorectal carcinoma tumors exhibiting positive staining of *Per1*, *Per2* and *Clock* were significantly larger than those exhibiting negative staining. Correspondingly, tumors with positive staining of *Per2* and *Clock* tended to be associated with deeper depth of invasion and a more advanced stage of cancer. Furthermore, an association was observed between positive-*Per2* expression and poorer overall survival outcome, though this was not technically significant. However, due to the relatively small sample size and short follow-up time of the present study, the prognostic impact of positive-*Per2* expression remains to be fully determined.

Clock genes are involved in cell cycle regulation ([@b21-ol-0-0-6876]). A positive factor, the Clock-Bmal1 dimer, is required for transcription initiation of the *Per* and *Cry* genes oscillating mechanism in the feedback mechanisms of the clock genes ([@b21-ol-0-0-6876]). By contrast, Per and Cry proteins are supposed to act as negative factors and promote oscillation ([@b22-ol-0-0-6876]). The Clock-Bmal1 dimer promotes transcription through the E-box of Wee1, suppressing the cell cycle at M-phase ([@b22-ol-0-0-6876]). The results of previous studies have demonstrated a connection between the alterations of clock genes, and cell cycle progression and proliferation through c-Myc/p21 signaling and the Wnt/β-catenin pathway, which are implicated in the molecular pathogenesis of colorectal cancer ([@b11-ol-0-0-6876],[@b17-ol-0-0-6876],[@b18-ol-0-0-6876]). Taken together with the results of the present study, this indicates that the imbalance of clock gene expression levels, which results in the dysregulation of cell cycle, may stimulate the adenoma-carcinoma transition and tumor progression during colorectal carcinogenesis. However, the current study did not address whether clock gene expression directly contributes to cell cycle dysregulation and tumorigenesis. The biological significance of *in situ* clock gene expression remains to be elucidated. Clock gene expression *in situ* may at least in part represent the dysregulated rhythms in carcinomas, therefore, future studies are required to address the molecular mechanisms by which the imbalance of clock genes expression contributes to dysregulated circadian rhythms and consequently, to tumorigenesis.

In conclusion, mRNA expression of key clock genes, including Per1, Per2, Cry1 and Cry2 was frequently found in carcinomas, but not in adenomas, using *in situ* hybridization. Also, the expression of some clock genes were associated with tumor size, and tended to be associated with depth of invasion and survival outcome. Therefore, the present study suggests that dysregulated clock gene expression may serve an important role in human colorectal tumorigenesis.
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![Expression of clock genes detected by *in situ* hybridization in colorectal carcinoma and surrounding normal mucosa. (A) *Per1*, (B) *Per2*, (C) *Cry1*, (D) *Clock*, (E) *Bmal1* and (F) *CK1*ε. Panels 1 and 2 represent carcinoma tissue with anti-sense probe (magnification, ×100 and ×400, respectively). Panels 3 and 4 represent carcinoma tissues with sense probe (magnification, ×100 and ×400, respectively). Panels 5 and 6 represent normal mucosa tissues with anti-sense and sense probes, respectively (magnification, ×100 for both). Per, Period circadian protein homolog; Cry1, Cryptochrome 1; Clock, Circadian locomoter output cycles protein kaput; Bmal1, Brain and Muscle ARNT-like Protein 1; CK1ε, Casein Kinase 1ε.](ol-14-05-5319-g00){#f1-ol-0-0-6876}

![Classification of the expression of clock genes by *in situ* hybridization. The intensity of staining in tumor cells was classified into four groups as: (A) None, (B) weak, (C) moderate and (D) strong. Magnification, ×100.](ol-14-05-5319-g01){#f2-ol-0-0-6876}

![Proportion of expression levels of clock genes in colorectal carcinoma (left panel) and adenoma (right panel). Differences between positive and negative were analyzed by Fisher\'s exact test. Per, period circadian protein homolog; Cry1, cryptochrome 1; Clock, circadian locomoter output cycles protein kaput; Bmal1, brain and muscle ARNT-like protein 1; CK1ε, casein kinase 1ε.](ol-14-05-5319-g02){#f3-ol-0-0-6876}

![Comparison of tumor size between positive and negative staining of each gene. (A) *Per1*, (B) *Per2*, (C) *Cry1*, (D) *Clock*, (E) *Bmal1* and (F) *CKI*ε. Boxes correspond to the inter-quartile ranges, with the lower boundary of the box representing the 25th percentile and the upper boundary representing the 75th percentile. Differences between groups were analyzed by Student\'s *t*-test. Per, period circadian protein homolog; Cry1, cryptochrome 1; Clock, circadian locomoter output cycles protein kaput; Bmal1, brain and muscle ARNT-like protein 1; CK1ε, casein kinase 1ε.](ol-14-05-5319-g03){#f4-ol-0-0-6876}

![Kaplan-Meier survival curves for *Per1* (A), *Per2* (B) and *Clock* (C). Survival differences were assessed using the log-rank test. Per, period circadian protein homolog; Clock, circadian locomoter output cycles protein kaput.](ol-14-05-5319-g04){#f5-ol-0-0-6876}

###### 

Associations between clock gene expression and clinicopathological variables.

                                          Per1              Per2                                                          Cry1                                                          Clock             Bmal1            CKIε                                                                                                                                                   
  ------------------------------ -------- -------- -------- ---------------------------------------------------- -------- -------- ---------------------------------------------------- -------- -------- ------- -------- -------- ---------------------------------------------------- -------- -------- ---------------------------------------------------- -------- -------- -------
  Age                                                       0.242                                                                  0.048                                                                  0.820                     0.931                                                                  0.423                                                                  0.727
    Mean                         65.1     63.7     67.6                                                          68.9     62.2                                                          65.1     65.9             65.6     65.4                                                          65.3     65.9                                                          65.8     64.6     
    Range                        33--84   33--81   43--84                                                        49--84   33--81                                                        33--84   41--84           41--81   33--84                                                        41--84   33--84                                                        33--84   46--80   
  Gender                                                    1                                                                      1                                                                      0.772                     0.563                                                                  0.774                                                                  0.333
    Male                         32       17       15                                                            16       16                                                            16       16               20       12                                                            20       12                                                            25       7        
    Female                       19       10       9                                                             9        10                                                            11       8                10       9                                                             11       8                                                             12       7        
  Tumor size (mm)                                           0.012^[a](#tfn1-ol-0-0-6876){ref-type="table-fn"}^                     0.011^[a](#tfn1-ol-0-0-6876){ref-type="table-fn"}^                     0.164                     0.009^[a](#tfn1-ol-0-0-6876){ref-type="table-fn"}^                     0.082^[a](#tfn1-ol-0-0-6876){ref-type="table-fn"}^                     0.342
    \<50                         29       20       9                                                             19       10                                                            18       11               22       7                                                             21       8                                                             23       6        
    ≥50                          22       7        15                                                            6        16                                                            9        13               8        14                                                            10       12                                                            14       8        
  Tumor location                                            0.782                                                                  1                                                                      0.577                     0.578                                                                  0.567                                                                  0.363
    Colon                        24       12       12                                                            12       12                                                            14       10               13       11                                                            16       8                                                             19       5        
    Rectum                       27       15       12                                                            13       14                                                            13       14               17       10                                                            15       12                                                            18       9        
  Histological differentiation                              0.636                                                                  0.972                                                                  0.991                     0.754                                                                  0.422                                                                  0.212
    Well                         34       17       17                                                            17       17                                                            18       16               20       14                                                            22       12                                                            27       7        
    Moderately                   13       7        6                                                             6        7                                                             7        6                7        6                                                             6        7                                                             7        6        
    Poorly                       0        0        0                                                             0        0                                                             0        0                0        0                                                             0        0                                                             0        0        
    Mucinous                     4        3        1                                                             2        2                                                             2        2                3        1                                                             3        1                                                             3        1        
  Depth of invasion                                         0.482                                                                  0.103                                                                  0.978                     0.303                                                                  0.580                                                                  0.240
    pT1                          5        3        2                                                             4        1                                                             3        2                4        1                                                             2        3                                                             2        3        
    pT2                          7        4        3                                                             5        2                                                             4        3                5        2                                                             4        3                                                             6        1        
    pT3                          31       14       17                                                            11       20                                                            16       15               15       16                                                            21       10                                                            22       9        
    pT4                          8        6        2                                                             5        3                                                             4        4                6        2                                                             4        4                                                             7        1        
  Depth of invasion                                         0.749                                                                  0.052                                                                  0.749                     0.315                                                                  0.502                                                                  0.715
    pT1-2                        12       7        5                                                             9        3                                                             7        5                9        3                                                             6        6                                                             8        4        
    pT3-4                        39       20       19                                                            16       23                                                            20       19               21       18                                                            25       14                                                            29       10       
  Lymph node metastasis                                     1                                                                      1                                                                      0.264                     1                                                                      1                                                                      0.363
    Absent                       27       14       13                                                            13       14                                                            12       15               16       11                                                            16       11                                                            18       9        
    Present                      24       13       11                                                            12       12                                                            15       9                14       10                                                            15       9                                                             19       5        
  Stage                                                     0.723                                                                  0.240                                                                  0.506                     0.180                                                                  0.987                                                                  0.363
    I                            9        6        3                                                             6        3                                                             5        4                8        1                                                             5        4                                                             6        3        
    II                           16       7        9                                                             6        10                                                            6        10               7        9                                                             10       6                                                             10       6        
    III                          21       11       10                                                            12       9                                                             13       8                12       9                                                             13       8                                                             18       3        
    IV                           5        3        2                                                             1        4                                                             3        2                3        2                                                             3        2                                                             3        2        
  Stage                                                     0.473                                                                  0.291                                                                  1                         0.064                                                                  0.724                                                                  0.692
    I                            9        6        3                                                             6        3                                                             5        4                8        1                                                             5        4                                                             6        3        
    II--IV                       42       21       21                                                            19       23                                                            22       20               22       20                                                            26       16                                                            31       11       

P\<0.05, indicates a significant difference. P, P-value; Per, period circadian protein homolog; Cry1, cryptochrome 1; Clock, circadian locomoter output cycles protein kaput; Bmal1, brain and muscle ARNT-like protein 1; CK1ε, casein kinase 1ε.
